Hjem
Per Eystein Lønnings bilde

Per Eystein Lønning

Professor
  • E-postPer.Lonning@uib.no
  • Telefon+47 55 97 20 10+47 55 97 20 27
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
  • Postadresse
    Postboks 7804
    5020 Bergen

Professor Per Eystein Lønning har arbeidet sammenhengende innenfor kreftbehandling og forskning fra 1982. Han har fra 1990 vært overlege ved Kreftavdelingen, Haukeland Sykehus, og fra 1992 Professor ved Universitetet i Bergen.  Han leder Brystkreftgruppen ved Mohn kreftforskningslaboratorium. Gruppen, som i alt teller vel 20 medlemmer, arbeider hovedsakelig med brystkreft men og med andre kreftsykdommer, som tykktarmskreft og føflekkkreft. Gruppen består av forskere i Mohn Kreftforskningslaboratorium samt leger ved Kreftavdelingen, der flere i likhet med Lønning arbeider både med pasientbehandling og laboratorie-forskning. Lønning har arbeidet både med virkningsmekanismene for hormonell behandling samt cellegift ved brystkreft, og i tillegg arbeidet med kreftrisiko-faktorer. Hovedfeltet nå er mekanismer for resistens mot cellegift. 

Vitenskapelig artikkel
  • 2013. Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue. PLOS ONE. 12 sider.
  • 2013. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin. Biochimica et Biophysica Acta - General Subjects. 2790-2797.
  • 2013. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma. PLOS ONE.
  • 2012. Poor-prognosis estrogen receptor-positive disease: present and future clinical solutions. Therapeutic advances in medical oncology.
  • 2012. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Research. 13 sider.
  • 2012. Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer. NMR in Biomedicine. 1033-1042.
  • 2012. Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers. BMC Cancer. 6 sider.
  • 2011. Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. Transcription.
  • 2010. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. European Journal of Cancer. 2127-2133.
  • 2010. Intratumoral estrogen disposition in breast cancer. Clinical Cancer Research. 1790-1801.
  • 2010. Impact of aromatase inhibitors on bone health in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 294-299.
  • 2010. Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome. Clinical Cancer Research. 3356-3367.
  • 2010. Evolution of endocrine adjuvant therapy for early breast cancer. Expert Opinion on Investigational Drugs. S19-S30.
  • 2010. Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: Of relevance to clinical understanding? Journal of Steroid Biochemistry and Molecular Biology. 288-293.
  • 2010. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Molecular Cancer. 13 sider.
  • 2010. Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity. BBA - Molecular Cell Research. 386-395.
  • 2010. Breast cancer aromatase expression evaluated by the novel antibody 677: Correlations to intra-tumor estrogen levels and hormone receptor status. Journal of Steroid Biochemistry and Molecular Biology. 237-241.
  • 2009. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. Journal of Steroid Biochemistry and Molecular Biology. 31-41.
  • 2009. Tailored targeted therapy for all: a realistic and worthwhile objective? Breast Cancer Research.
  • 2009. Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. British Journal of Cancer. 1253-1260.
  • 2009. Molecular classes of breast cancer and their clinical relevance. Current Breast Cancer Reports. 183-189.
  • 2009. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Research. 5331-5339.
  • 2009. A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide. Clinical Cancer Research. 4165-4173.
  • 2008. The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 5182-5194.
  • 2008. Pathway based analysis of SNPs with relevance to 5-FU therapy: Relation to intratumoral mRNA expression and survival. International Journal of Cancer. 577-585.
  • 2008. Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels. Clinical Cancer Research. 6330-6335.
  • 2008. GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas. Cancer Research. 5562-5571.
  • 2008. Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference? Anti-Cancer Drugs. S11-S13.
  • 2008. Experience with exemestane in the treatment of early and advanced breast cancer. Expert Opinion on Drug Metabolism & Toxicology. 987-997.
  • 2008. Endocrine treatment - "old-fashioned" therapy becoming redundant in an era of molecular medicine? Breast Care. 388-390.
  • 2008. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLOS ONE. 15 sider.
  • 2008. Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression. Journal of Steroid Biochemistry and Molecular Biology. 196-202.
  • 2008. Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? The Oncologist. 829-837.
  • 2008. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. Journal of Steroid Biochemistry and Molecular Biology. 90-95.
  • 2007. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncologica.
  • 2007. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. Journal of Steroid Biochemistry and Molecular Biology. 27-34.
  • 2007. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. The Lancet. 559-570.
  • 2007. Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Research. 7267-7278.
  • 2007. Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Research. 7267-7278.
  • 2007. Mutations and polymorphisms of the p21B transcript in breast cancer. International Journal of Cancer. 908-910.
  • 2007. Breast cancer prognostication and prediction: are we making progress? Annals of Oncology. viii3-viii7.
  • 2007. Aromatase inhibitors-Socioeconomical issues. Journal of Steroid Biochemistry and Molecular Biology. 55-61.
  • 2007. Adjuvant endocrine treatment of early breast cancer. Hematology/Oncology Clinics of North America. 223-238.
  • 2007. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenetics & Genomics. 127-136.
  • 2006. The novel p21 polymorphism p21(G251A) is associated with locally advanced breast cancer. Clinical Cancer Research. 6000-6004.
  • 2006. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunology and Immunotherapy. 1280-1284.
  • 2006. Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA. Journal of Cell Science. 3284-3295.
  • 2006. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Molecular Cancer Therapeutics. 2914-2918.
  • 2006. Expression of full-length p35 and its isoform DELTAp53 in breast carcinomas in relation to mutation status and clinical parameters. Molecular Cancer. 47.
  • 2006. Commentary on: Does adjuvant therapy with letrozole improve survival in postmenopausal women with early-stage breast cancer? Nature Clinical Practice Oncology. 356-357.
  • 2006. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study. European Journal of Cancer. 2968-75.
  • 2006. Antitumor efficacy improved by local delivery of species-specific endostatin. Journal of Neurosurgery. 118-128.
  • 2006. Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma. Journal of Gene Medicine. 1131-1140.
  • 2006. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. Genes, Chromosomes and Cancer. 1155-1163.
  • 2005. Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin. Oncology Reports. 525-530.
  • 2005. Genomics-based prognosis and therapeutic prediction in breast cancer. The Journal of the National Comprehensive Cancer Network. 291-300.
  • 2005. Genomics in breast cancer - therapeutic implications? Nature Clinical Practice Oncology. 26-33.
  • 2005. Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: Clinical implication. Clinical Cancer Research. 878s-883s.
  • 2005. Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 105-111.
  • 2005. Aromatasehemmere i behandling av brystkreft. Tidsskrift for Den norske legeforening. 723-728.
  • 2005. Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncologica. 23-31.
  • 2005. Aromatase inhibitors - socio-economical issues. Journal of Steroid Biochemistry and Molecular Biology. 137-142.
  • 2004. PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication. Experimental Cell Research. 58-73.
  • 2003. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clinical Cancer Research. 5582-5588.
  • 2003. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clinical Cancer Research. 5582-5588.
  • 2003. Study of suboptimum treatment response: lessons from breast cancer. The Lancet. 177-185.
  • 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America. 8418-8423.
  • 2003. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer. 438-446.
  • 2003. Predictive value of tumour cell proliferation in locally advanced breast cancer treated neoadjuvant chemotherapy. European Journal of Cancer. 438-446.
  • 2003. Pharmacokinetics of third-generation aromatase inhibitors. Seminars in Oncology. 23-32.
  • 2003. Development of aromatase inhibitors and their pharmacologic profile. American Journal of Clinical Oncology. S3-S8.
  • 2003. Clinical pharmacokinetics of aromatase inhibitors and inactivators. Clinical Pharmacokinetics. 619-631.
  • 2002. The role of aromatase inactivators in the treatment of breast cancer. International Journal of Clinical Oncology. 265-270.
  • 2002. The TP53 Codon 72 Polymorphism May Affect the Function of TP53 Mutations in Breast Carcinomas but not in Colorectal Carcinomas. Cancer Epidemiology, Biomarkers and Prevention. 1684-1688.
  • 2002. The IGF-system in healthy pre- and postmenopausal women: relations to demographic variables and sex-steroids. Journal of Steroid Biochemistry and Molecular Biology. 95-102.
  • 2002. Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer. Breast Cancer Research and Treatment. 161-175.
  • 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proceedings of the National Academy of Sciences of the United States of America. 12963-12968.
  • 2002. Letrozole is more effective than anastrozole in suppressing total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients. American Journal of Oncology Review. 99-102.
  • 2002. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. Journal of Clinical Oncology. 751-757.
  • 2002. Aromatase inhibitors and inactivators for breast cancer therapy. Drugs & Aging. 277-298.
  • 2002. Adeno-associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors. Human Gene Therapy. 1115-1125.
  • 2001. Pharmacokinetics and metabolism of formestane in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 39-47.
  • 2001. Microarrays in primary breast cancer ¿ lessons from chemotherapy studies. Endocrine-related cancer. Endocrine-Related Cancer. 259-263.
  • 2000. Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. Cancer Treatment Reviews. 205-227.
  • 2000. Screening breast cancer patients for ATM mutations found in Norwegian AT patients. British Journal of Cancer. 1650-1653.
  • 2000. Pharmacology and clinical experience with exemestane. Expert Opinion on Investigational Drugs. 1897-1905.
  • 2000. Molecular portraits of human breast tumours. Nature. 747-52.
  • 2000. Molecular portraits of human breast tumours. Nature. 747-752.
  • 2000. Is there a growing role for endocrine therapy in the treatment of breast cancer? Drugs. 11-21.
  • 2000. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene. 1329-1333.
  • 2000. Exemestane in breast cancer: Current status and future directions. Clinical Breast Cancer. S28-S33.
  • 2000. Endocrine therapy for treatment of breast cancer. Polish Oncology. 50-53.
  • 2000. Clinico-pharmacological aspects of different hormone treatments. European Journal of Cancer. S81-S82.
  • 2000. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. Journal of Clinical Oncology. 2234-2244.
  • 2000. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. Journal of Clinical Oncology. 2234-2244.
  • 2000. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. Journal of Steroid Biochemistry and Molecular Biology. 259-264.
  • 2000. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. Journal of Steroid Biochemistry and Molecular Biology. 259-264.
  • 1998. Pharmacological profiles of exemestane and formestane steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Research and Treatment. 45-52.
  • 1998. Pharmacological and clinical profile of anastrozole. Breast Cancer Research and Treatment. s53-s57.
  • 1998. Microencapsulated octreotide pamoate in advanced cancer. British Journal of Cancer. 14-20.
  • 1998. Kinetics of plasma total homocysteine in patients receiving high- dose methotrexate therapy. Clinical Chemistry. 1987-1989.
  • 1998. Influence of treatment with onapristone on the IGF-system in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 159-163.
  • 1998. Influence of treatment with aminoglutethimide on plasma and red-blood-cell gluthatione status in breast cancer patients. Cancer Chemotherapy and Pharmacology. 46-52.
  • 1998. Influence of Droloxifene on Metastatic Breast Cancer as First Line Endocrine Treatment. Acta Oncologica. 365-368.
  • 1998. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breat cancer patients. Clinical Cancer Research. 2089-2093.
  • 1997. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. Journal of Steroid Biochemistry and Molecular Biology. 255-260.
  • 1997. Exemestane experience in breast cancer treatment. Journal of Steroid Biochemistry and Molecular Biology. 151-155.
  • 1997. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clinical Cancer Research. 1101-1108.
  • 1997. Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • 1997. Effects of hormones on the plasma level of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • 1997. Differential influence of carbamazepine and valproate monotherapy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. Journal of Endocrinology. 307-312.
  • 1997. Different effects of carbamazepine and valproate monotheraphy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. Journal of Endocrinology. 307-312.
  • 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • 1997. Anastrozole - A new generation in aromatase inhibition: Clinical pharmacology. Oncology. 11-14.
  • 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • 1996. Spesific TP53 gene mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; Clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • 1996. Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Research and Treatment. 335-341.
  • 1996. Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-I IGFBP-3 in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 167-171.
  • 1996. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. British Journal of Cancer. 1286-1291.
  • 1996. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisatin and plasma oestrogen levels in post-menopausal women with breast cancer. British Journal of Cancer. 1286-1291.
  • 1995. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clinical Endocrinology. 23-30.
  • 1995. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
  • 1995. Insulin-like growth factors in breast and prostatic cancer. Endocrine-Related Cancer. 153-169.
  • 1995. Influence of tamoxifen on sex hormones, gonadotropins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
  • 1995. Determination of droloxifene and two metabolites in serum by high-pressure liquid chromatography. Therapeutic Drug Monitoring. 259-265.
  • 1994. Primærbehandling av lokalavansert brystkreft med bruk av neoadjuvant kjemoterapi. Tidsskrift for Den norske legeforening. 668-670.
  • 1994. Pharmacokinetics of anti-endocrine agents. Cancer Surveys. S. 343-370.
  • 1993. Use of endocrine therapy to study the biology of breast cancer. Cancer Treatment Reviews. 65-77.
  • 1993. Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxy-androstenedione. British Journal of Cancer. 393-398.
  • 1993. Pharmacokinetics of antiendocrine agents. Cancer Surveys. 343-370.
  • 1993. Pharmacokinetics of antiendocrine agents. Cancer Surveys. 343-370.
  • 1993. Dose response evaluation - Use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio. Clinical Pharmacokinetics. 1-5.
  • 1993. Analysis of Phase I and Phase II metabolites of tamoxifen in breast cancer patients. Drug Metabolism And Disposition. 1119-1124.
  • 1992. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aramotisation in breast cancer patients. European Journal of Cancer. 1712-1716.
  • 1992. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. British Journal of Cancer. 692-697.
  • 1992. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • 1992. Influence of tamoxifen on plasma levels of insulinelike growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Research. 4719-4723.
  • 1992. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Research. 4719-4723.
  • 1992. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patient on 4-hydroxyandrostenedione treatment. Breast Cancer Research and Treatment. 57-62.
  • 1992. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clinical Pharmacokinetics. 327-358.
  • 1992. Aromatase inhibitors in malignant diseases of aging. Drugs & Aging. 530-545.
  • 1992. Aromatase activity, plasma oestradiol and their correlation with demographic indices in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 769-771.
  • 1991. Wie wirkungsvoll ist das Mammographie-Screening? Deutsche Medizinische Wochenschrift. 108-112.
  • 1991. Treatment of early breast cancer with conservation of the breast. Acta Oncologica. 779-792.
  • 1991. Treatment of breast cancer with aromatase inhibitors. Medicamentos de actualidad. 117-132.
  • 1991. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. British Journal of Cancer. 789-793.
  • 1991. Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl) piperidine-2,6-dione in patients with postmenopausal breast cancer. Cancer Chemotherapy and Pharmacology. 367-372.
  • 1991. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. Journal of enzyme inhibition (Print). 315-325.
  • 1991. Leser-Zuschriften - Mammographie-Screening. Deutsche Medizinische Wochenschrift. 636-637.
  • 1991. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl) piperidine-2,6-dione ("pyridoglutethimide") in postmenopausal breast cancer patients. British Journal of Cancer. 887-894.
  • 1991. Distribution of tamoxifen and metabolites into brain tissue metastases in breast cancer patients. British Journal of Cancer. 641-645.
  • 1991. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. British Journal of Cancer. 641-645.
  • 1991. Distribution of Tamoxifen and meta-bolites into brain tissue and brain metastases in brain cancer patients. British Journal of Cancer. 641-645.
  • 1991. Aromatase inhibitors - future prospects. Int Congr Symp Series. 55-59.
  • 1990. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer-2. A differential effect of megestrol acetate a medroxyprogesterone acetate on serum estrone sulfate and sex hormone binding globulin. Journal of Steroid Biochemistry. 105-109.
  • 1990. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer-1. General findings. Journal of Steroid Biochemistry. 99-104.
  • 1990. Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megastrol acetate in postmenopausal patients with advanced brea cancer. Cancer Chemotherapy and Pharmacology. 101-105.
  • 1990. Decreased serum concentrations of tamoxifen and its metabolites induced by aminogluethimide. Cancer Research. 5851-5857.
Vitenskapelig foredrag
  • 2012. Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.
  • 2011. GDPD5 expression correlates with choline metabolite profiles in human breast cancer.
  • 2010. Predicting long-term survival for breast cancer patients by HR MAS metabolic profiling during neoadjuvant chemotherapy.
  • 2010. Predicting long-term breast cancer survival in patients receiving neoadjuvant chemotherapy by MR metabolic profiling.
  • 1999. Neoadjuvant Treatment with Anastrozole ('ARIMIDEX') Causes Profound Suppression of Intra-Tumor Estrogen Levels.
  • 1999. Comparison of the effects of neoadjuvant 'Arimidex'(Anastrozole) on plasma and intra-tumor tissue estrogen levels in postmenopausalbreast cancer patients.
  • 1995. A randomized, double-blind, multicentre crossover trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer.
  • 1994. Treatment of postmenopausal breast cancer patients with the steroidal aromatase inhibitor Exemestane (FCE 24304).
  • 1994. Influence of megestrol acetate, aminoglutethimide and 4-hydroxyandrostendione on plasma IGF-I in breast cancer patients.
Vitenskapelig antologi/Konferanseserie
  • 2004. Expression profiling of breast cancer: From molecular portraits to clinical utility. John Wiley & Sons.
Sammendrag/abstract
  • 2010. Exploring chemoresistance in vivo; are we making progress. European Journal of Cancer. 155-155.
  • 2009. Proteomics analysis of tissue samples obtained before and during letrozole treatment in postmenopausal patients with locally advanced breast cancer. Cancer Research. 214S-214S.
  • 2009. DETERMINANTS OF INTRATUMOURAL OESTRADIOL (E2) CONCENTRATIONS IN POSTMENOPAUSAL BREAST CANCER: ROLES FOR OESTROGEN RECEPTOR (ER) AND 17B-HYDROXYSTEROID DEHYDROGENASE 7 (HSD17B7). Annals of Oncology. 51-52.
  • 2008. ER/PGR and prediction of response to hormonotherapy. Can we do better? Annals of Oncology. 29-29.
  • 2008. Are there any difference between third-generation aromatase inhibitors? European Journal of Cancer. 52-52.
  • 2008. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. 592-592.
  • 2007. Promotor hypermethylation of MGMT, RAR-beta2, RASSF1A and p16 in metastatic malignant melanoma. Proceedings of the American Association of Cancer Research. 684.
  • 2007. Biological lessons from adjuvant therapy. European Journal of Cancer. 25-25.
  • 2007. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment.
  • 2005. The SNP309HDM2 polymorphism is associated with chemoresistance and poor survival in breast cancers harboring mutations in the TP53 gene. Breast Cancer Research and Treatment. S160-S160.
Vitenskapelig oversiktsartikkel/review
  • 2016. Incomplete estrogen suppression with gonadotropin-releasing hormone agonists may reduce clinical efficacy in premenopausal women with early breast cancer. 1580-1583.
  • 2015. Estradiol measurement in translational studies of breast cancer. 26-31.
  • 2014. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. 681-700.
  • 2013. Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. 5315-5330.
  • 2013. Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. R183-R201.
  • 2012. P53 and its molecular basis to chemoresistance in breast cancer. S23-S30.
  • 2011. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. 503-514.
  • 2011. Exploring breast cancer estrogen disposition: The basis for endocrine manipulation. 4948-4958.
  • 2010. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. 1825-1836.
  • 2010. Molecular basis for therapy resistance. 284-300.
  • 2009. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? 527-535.
  • 2009. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. 6-22.
  • 2009. Additive endocrine therapy for advanced breast cancer - back to the future. 1092-1101.
  • 2008. Indications and limitations of third-gene ration aromatase inhibitors. 723-739.
  • 2007. Breast cancer prognostication and prediction in the postgenomic era. 1293-1306.
  • 2006. Aromatase inhibitors as adjuvant treatment of breast cancer. 53-61.
  • 2004. Aromatase inhibitors in breast cancer. 179-189.

Se fullstendig oversikt over publikasjoner i CRIStin.

Kompetansefelt